主营介绍

运营业务数据

最新公告日期:2016-04-26 
业务名称 2015-12-31 2014-12-31 2013-12-31
医药原料药及中间体库存量(Kg) 3.59万 - -
医药制剂库存量(瓶/盒/片) 2317.94万 2315.65万 2880.00万
医疗器械库存量(套) 46.00 81.00 72.00
医药原料药库存量(Kg) - 3.53万 2.08万

主营构成分析

{"2017-06-30":{"YYSR":{"1":[["\u533b\u836f","69590.22"],["\u533b\u7597\u670d\u52a1","5790.27"],["\u533b\u7597\u5668\u68b0","616.89"]],"2":[["\u539f\u6599\u836f\u53ca\u4e2d\u95f4\u4f53","22186.82"],["\u5934\u5b62\u5236\u5242\u7cfb\u5217","21209.32"],["\u5176\u4ed6\u54c1\u79cd","19963.19"],["\u80a0\u80c3\u5eb7","6230.88"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",6407.16]],"3":[["\u56fd\u5185","75193.97"],["\u56fd\u5916","1126.32"]]},"YYCB":{"1":[["\u533b\u836f","38740.44"],["\u533b\u7597\u670d\u52a1","5354.12"],["\u533b\u7597\u5668\u68b0","195.75"]],"2":[["\u539f\u6599\u836f\u53ca\u4e2d\u95f4\u4f53","19482.34"],["\u5934\u5b62\u5236\u5242\u7cfb\u5217","8314.92"],["\u5176\u4ed6\u54c1\u79cd","9646.33"],["\u80a0\u80c3\u5eb7","1296.85"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",5549.87]],"3":[["\u56fd\u5185","43684.52"],["\u56fd\u5916","605.79"]]},"LRBL":{"1":[["\u533b\u836f","97.30"],["\u533b\u7597\u670d\u52a1","1.38"],["\u533b\u7597\u5668\u68b0","1.33"]],"2":[["\u539f\u6599\u836f\u53ca\u4e2d\u95f4\u4f53","8.53"],["\u5934\u5b62\u5236\u5242\u7cfb\u5217","40.67"],["\u5176\u4ed6\u54c1\u79cd","32.54"],["\u80a0\u80c3\u5eb7","15.56"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",2.71]],"3":[["\u56fd\u5185","98.37"],["\u56fd\u5916","1.63"]]}},"2016-12-31":{"YYSR":{"1":[["\u533b\u836f","144881.10"],["\u533b\u7597\u5668\u68b0","2100.16"],["\u533b\u7597\u670d\u52a1\u8d39","1785.53"]],"2":[["\u5176\u4ed6\u54c1\u79cd","56222.39"],["\u539f\u6599\u836f\u53ca\u4e2d\u95f4\u4f53","35785.28"],["\u5934\u5b62\u5236\u5242\u7cfb\u5217","35657.68"],["\u80a0\u80c3\u5eb7","17215.74"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",3885.69]],"3":[["\u56fd\u5185","148921.45"],["\u56fd\u5916","1973.90"]]},"YYCB":{"1":[["\u533b\u836f","67932.53"],["\u533b\u7597\u5668\u68b0",""],["\u533b\u7597\u670d\u52a1\u8d39",""]],"2":[["\u5176\u4ed6\u54c1\u79cd","16884.49"],["\u539f\u6599\u836f\u53ca\u4e2d\u95f4\u4f53","28534.14"],["\u5934\u5b62\u5236\u5242\u7cfb\u5217","19624.10"],["\u80a0\u80c3\u5eb7","2889.80"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",0]],"3":[["\u56fd\u5185","67330.41"],["\u56fd\u5916",""]]},"LRBL":{"1":[["\u533b\u836f","100.00"],["\u533b\u7597\u5668\u68b0",""],["\u533b\u7597\u670d\u52a1\u8d39",""]],"2":[["\u5176\u4ed6\u54c1\u79cd","51.12"],["\u539f\u6599\u836f\u53ca\u4e2d\u95f4\u4f53","9.42"],["\u5934\u5b62\u5236\u5242\u7cfb\u5217","20.84"],["\u80a0\u80c3\u5eb7","18.62"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",0]],"3":[["\u56fd\u5185","100.00"],["\u56fd\u5916",""]]}},"2016-06-30":{"YYSR":{"1":[["\u533b\u836f","75169.77"],["\u533b\u7597\u5668\u68b0","802.86"]],"2":[["\u539f\u6599\u836f\u53ca\u5176\u4e2d\u95f4\u4f53","24815.84"],["\u5934\u5b62\u5236\u5242","20620.07"],["\u5176\u5b83","16450.93"],["\u80a0\u80c3\u5eb7","11908.98"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",2176.81]],"3":[["\u56fd\u5185","75312.78"],["\u56fd\u5916","659.86"]]},"YYCB":{"1":[["\u533b\u836f","45550.06"],["\u533b\u7597\u5668\u68b0","258.36"]],"2":[["\u539f\u6599\u836f\u53ca\u5176\u4e2d\u95f4\u4f53","21371.88"],["\u5934\u5b62\u5236\u5242","13274.80"],["\u5176\u5b83","8828.01"],["\u80a0\u80c3\u5eb7","1831.71"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",502.02]],"3":[["\u56fd\u5185","45483.36"],["\u56fd\u5916","325.06"]]},"LRBL":{"1":[["\u533b\u836f","98.19"],["\u533b\u7597\u5668\u68b0","1.81"]],"2":[["\u539f\u6599\u836f\u53ca\u5176\u4e2d\u95f4\u4f53","11.42"],["\u5934\u5b62\u5236\u5242","24.35"],["\u5176\u5b83","25.27"],["\u80a0\u80c3\u5eb7","33.41"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",5.56]],"3":[["\u56fd\u5185","98.89"],["\u56fd\u5916","1.11"]]}}}
{"YYSR":{"chartWrap1":[{"name":"\u533b\u836f","timeData":["2017-06-30","2016-12-31","2016-06-30"],"lineData":[69590.22,144881.1,75169.77],"columnData":[91.57,97.39,98.94],"unit":["6.96\u4ebf","14.49\u4ebf","7.52\u4ebf"]},{"name":"\u533b\u7597\u670d\u52a1","timeData":["2017-06-30"],"lineData":[5790.27],"columnData":[7.62],"unit":["5790.27\u4e07"]},{"name":"\u533b\u7597\u5668\u68b0","timeData":["2017-06-30","2016-12-31","2016-06-30"],"lineData":[616.89,2100.16,802.86],"columnData":[0.81,1.41,1.06],"unit":["616.89\u4e07","2100.16\u4e07","802.86\u4e07"]},{"name":"\u533b\u7597\u670d\u52a1\u8d39","timeData":["2016-12-31"],"lineData":[1785.53],"columnData":[1.2],"unit":["1785.53\u4e07"]}],"chartWrap2":[{"name":"\u539f\u6599\u836f\u53ca\u4e2d\u95f4\u4f53","timeData":["2017-06-30","2016-12-31"],"lineData":[22186.82,35785.28],"columnData":[29.19,24.05],"unit":["2.22\u4ebf","3.58\u4ebf"]},{"name":"\u5934\u5b62\u5236\u5242\u7cfb\u5217","timeData":["2017-06-30","2016-12-31"],"lineData":[21209.32,35657.68],"columnData":[27.91,23.97],"unit":["2.12\u4ebf","3.57\u4ebf"]},{"name":"\u5176\u4ed6\u54c1\u79cd","timeData":["2017-06-30","2016-12-31"],"lineData":[19963.19,56222.39],"columnData":[26.27,37.79],"unit":["2.00\u4ebf","5.62\u4ebf"]},{"name":"\u80a0\u80c3\u5eb7","timeData":["2017-06-30","2016-12-31","2016-06-30"],"lineData":[6230.88,17215.74,11908.98],"columnData":[8.2,11.57,15.68],"unit":["6230.88\u4e07","1.72\u4ebf","1.19\u4ebf"]},{"name":"\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1","timeData":["2017-06-30","2016-12-31","2016-06-30"],"lineData":[6407.16,3885.69,2176.81],"columnData":[8.43,2.61,2.87],"unit":["6407.16\u4e07","3885.69\u4e07","2176.81\u4e07"]},{"name":"\u539f\u6599\u836f\u53ca\u5176\u4e2d\u95f4\u4f53","timeData":["2016-06-30"],"lineData":[24815.84],"columnData":[32.66],"unit":["2.48\u4ebf"]},{"name":"\u5934\u5b62\u5236\u5242","timeData":["2016-06-30"],"lineData":[20620.07],"columnData":[27.14],"unit":["2.06\u4ebf"]},{"name":"\u5176\u5b83","timeData":["2016-06-30"],"lineData":[16450.93],"columnData":[21.65],"unit":["1.65\u4ebf"]}],"chartWrap3":[{"name":"\u56fd\u5185","timeData":["2017-06-30","2016-12-31","2016-06-30"],"lineData":[75193.97,148921.45,75312.78],"columnData":[98.52,98.69,99.13],"unit":["7.52\u4ebf","14.89\u4ebf","7.53\u4ebf"]},{"name":"\u56fd\u5916","timeData":["2017-06-30","2016-12-31","2016-06-30"],"lineData":[1126.32,1973.9,659.86],"columnData":[1.48,1.31,0.87],"unit":["1126.32\u4e07","1973.90\u4e07","659.86\u4e07"]}]},"YYCB":{"chartWrap1":[{"name":"\u533b\u836f","timeData":["2017-06-30","2016-12-31","2016-06-30"],"lineData":[38740.44,67932.53,45550.06],"columnData":[87.47,100,99.44],"unit":["3.87\u4ebf","6.79\u4ebf","4.56\u4ebf"]},{"name":"\u533b\u7597\u670d\u52a1","timeData":["2017-06-30"],"lineData":[5354.12],"columnData":[12.09],"unit":["5354.12\u4e07"]},{"name":"\u533b\u7597\u5668\u68b0","timeData":["2017-06-30","2016-12-31","2016-06-30"],"lineData":[195.75,0,258.36],"columnData":[0.44,0,0.56],"unit":["195.75\u4e07","0.00","258.36\u4e07"]},{"name":"\u533b\u7597\u670d\u52a1\u8d39","timeData":["2016-12-31"],"lineData":[0],"columnData":[0],"unit":["0.00"]}],"chartWrap2":[{"name":"\u539f\u6599\u836f\u53ca\u4e2d\u95f4\u4f53","timeData":["2017-06-30","2016-12-31"],"lineData":[19482.34,28534.14],"columnData":[43.99,42],"unit":["1.95\u4ebf","2.85\u4ebf"]},{"name":"\u5934\u5b62\u5236\u5242\u7cfb\u5217","timeData":["2017-06-30","2016-12-31"],"lineData":[8314.92,19624.1],"columnData":[18.77,28.89],"unit":["8314.92\u4e07","1.96\u4ebf"]},{"name":"\u5176\u4ed6\u54c1\u79cd","timeData":["2017-06-30","2016-12-31"],"lineData":[9646.33,16884.49],"columnData":[21.78,24.85],"unit":["9646.33\u4e07","1.69\u4ebf"]},{"name":"\u80a0\u80c3\u5eb7","timeData":["2017-06-30","2016-12-31","2016-06-30"],"lineData":[1296.85,2889.8,1831.71],"columnData":[2.93,4.25,4],"unit":["1296.85\u4e07","2889.80\u4e07","1831.71\u4e07"]},{"name":"\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1","timeData":["2017-06-30","2016-12-31","2016-06-30"],"lineData":[5549.87,0,502.02],"columnData":[12.53,0,1.09],"unit":["5549.87\u4e07","0.00","502.02\u4e07"]},{"name":"\u539f\u6599\u836f\u53ca\u5176\u4e2d\u95f4\u4f53","timeData":["2016-06-30"],"lineData":[21371.88],"columnData":[46.65],"unit":["2.14\u4ebf"]},{"name":"\u5934\u5b62\u5236\u5242","timeData":["2016-06-30"],"lineData":[13274.8],"columnData":[28.98],"unit":["1.33\u4ebf"]},{"name":"\u5176\u5b83","timeData":["2016-06-30"],"lineData":[8828.01],"columnData":[19.27],"unit":["8828.01\u4e07"]}],"chartWrap3":[{"name":"\u56fd\u5185","timeData":["2017-06-30","2016-12-31","2016-06-30"],"lineData":[43684.52,67330.41,45483.36],"columnData":[98.63,100,99.29],"unit":["4.37\u4ebf","6.73\u4ebf","4.55\u4ebf"]},{"name":"\u56fd\u5916","timeData":["2017-06-30","2016-12-31","2016-06-30"],"lineData":[605.79,0,325.06],"columnData":[1.37,0,0.71],"unit":["605.79\u4e07","0.00","325.06\u4e07"]}]},"LRBL":{"chartWrap1":[{"name":"\u533b\u836f","timeData":["2017-06-30","2016-12-31","2016-06-30"],"lineData":[97.3,100,98.19],"columnData":[97.3,100,98.19],"unit":["97.30\u4e07","100.00\u4e07","98.19\u4e07"]},{"name":"\u533b\u7597\u670d\u52a1","timeData":["2017-06-30"],"lineData":[1.38],"columnData":[1.38],"unit":["1.38\u4e07"]},{"name":"\u533b\u7597\u5668\u68b0","timeData":["2017-06-30","2016-12-31","2016-06-30"],"lineData":[1.33,0,1.81],"columnData":[1.33,0,1.81],"unit":["1.33\u4e07","0.00","1.81\u4e07"]},{"name":"\u533b\u7597\u670d\u52a1\u8d39","timeData":["2016-12-31"],"lineData":[0],"columnData":[0],"unit":["0.00"]}],"chartWrap2":[{"name":"\u539f\u6599\u836f\u53ca\u4e2d\u95f4\u4f53","timeData":["2017-06-30","2016-12-31"],"lineData":[8.53,9.42],"columnData":[8.53,9.42],"unit":["8.53\u4e07","9.42\u4e07"]},{"name":"\u5934\u5b62\u5236\u5242\u7cfb\u5217","timeData":["2017-06-30","2016-12-31"],"lineData":[40.67,20.84],"columnData":[40.67,20.84],"unit":["40.67\u4e07","20.84\u4e07"]},{"name":"\u5176\u4ed6\u54c1\u79cd","timeData":["2017-06-30","2016-12-31"],"lineData":[32.54,51.12],"columnData":[32.54,51.12],"unit":["32.54\u4e07","51.12\u4e07"]},{"name":"\u80a0\u80c3\u5eb7","timeData":["2017-06-30","2016-12-31","2016-06-30"],"lineData":[15.56,18.62,33.41],"columnData":[15.56,18.62,33.41],"unit":["15.56\u4e07","18.62\u4e07","33.41\u4e07"]},{"name":"\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1","timeData":["2017-06-30","2016-12-31","2016-06-30"],"lineData":[2.71,0,5.56],"columnData":[2.71,0,5.56],"unit":["2.71\u4e07","0.00","5.56\u4e07"]},{"name":"\u539f\u6599\u836f\u53ca\u5176\u4e2d\u95f4\u4f53","timeData":["2016-06-30"],"lineData":[11.42],"columnData":[11.42],"unit":["11.42\u4e07"]},{"name":"\u5934\u5b62\u5236\u5242","timeData":["2016-06-30"],"lineData":[24.35],"columnData":[24.35],"unit":["24.35\u4e07"]},{"name":"\u5176\u5b83","timeData":["2016-06-30"],"lineData":[25.27],"columnData":[25.27],"unit":["25.27\u4e07"]}],"chartWrap3":[{"name":"\u56fd\u5185","timeData":["2017-06-30","2016-12-31","2016-06-30"],"lineData":[98.37,100,98.89],"columnData":[98.37,100,98.89],"unit":["98.37\u4e07","100.00\u4e07","98.89\u4e07"]},{"name":"\u56fd\u5916","timeData":["2017-06-30","2016-12-31","2016-06-30"],"lineData":[1.63,0,1.11],"columnData":[1.63,0,1.11],"unit":["1.63\u4e07","0.00","1.11\u4e07"]}]}}

营业收入 X

单位(%) 单位(万元)
注:通常在中报、年报时披露 
业务名称 营业收入(元) 收入比例 营业成本(元) 成本比例 利润比例 毛利率
按行业 医药 6.96亿 91.57% 3.87亿 87.47% 97.30% 44.33%
医疗服务 5790.27万 7.62% 5354.12万 12.09% 1.38% 7.53%
医疗器械 616.89万 0.81% 195.75万 0.44% 1.33% 68.27%
按产品 原料药及中间体 2.22亿 29.19% 1.95亿 43.99% 8.53% 12.19%
头孢制剂系列 2.12亿 27.91% 8314.92万 18.77% 40.67% 60.80%
其他品种 2.00亿 26.27% 9646.33万 21.78% 32.54% 51.68%
肠胃康 6230.88万 8.20% 1296.85万 2.93% 15.56% 79.19%
医疗服务费 5790.27万 7.62% 5354.12万 12.09% 1.38% 7.53%
医疗器械 616.89万 0.81% 195.75万 0.44% 1.33% 68.27%
按地区 国内 7.52亿 98.52% 4.37亿 98.63% 98.37% 41.90%
国外 1126.32万 1.48% 605.79万 1.37% 1.63% 46.21%

董事会经营评述

  一、概述
  2017年上半年,随着供给侧改革的持续深化,从医药行业药品领域的仿制药一致性评价,到流通领域的两票制,再到医疗领域的分级诊疗体系,及医保目录调整等措施的不断实施,制药企业将加速分化,未来医药市场将会转向以创新药或者高质量的仿制药为主,同时医疗服务将更注重经营管理和服务质量。
  公司根据2017年度经营计划的部署,稳健发展传统制药业务,优化管理架构,加快推进研发创新,推进医院投资项目,拓展医疗服务业务板块。
  报告期内,公司有序推进了以下主要工作:
  (一)加快推动新药研发、创新成果转化
  公司继续推进注射用盐酸苯达莫司汀、奥美拉唑碳酸氢钠干混悬剂Ⅱ期临床试验,并确定氟... 查看全部▼

  一、概述
  2017年上半年,随着供给侧改革的持续深化,从医药行业药品领域的仿制药一致性评价,到流通领域的两票制,再到医疗领域的分级诊疗体系,及医保目录调整等措施的不断实施,制药企业将加速分化,未来医药市场将会转向以创新药或者高质量的仿制药为主,同时医疗服务将更注重经营管理和服务质量。
  公司根据2017年度经营计划的部署,稳健发展传统制药业务,优化管理架构,加快推进研发创新,推进医院投资项目,拓展医疗服务业务板块。
  报告期内,公司有序推进了以下主要工作:
  (一)加快推动新药研发、创新成果转化
  公司继续推进注射用盐酸苯达莫司汀、奥美拉唑碳酸氢钠干混悬剂Ⅱ期临床试验,并确定氟非尼酮、多立培南、替比培南等产品临床研究方案及计划。报告期内,公司筛选的部分仿制药品也正按计划开展质量和疗效一致性评价的研究开发工作。
  (二)推进再融资项目,为公司后续发展注入资金支持
  公司于2017年1月4日完成2017年度第一期非公开定向债务融资工具的发行工作,发行总额为5亿元;2017年5月17日完成2017年度第二期非公开定向债务融资工具的发行工作,发行总额为5亿元;2017年3月22日完成了2017年度第一期超短期融资券的发行,发行总额5亿元;2017年6月27日,公司2017年面向合格投资者公开发行公司债券(第一期)完成发行,募集资金规模13亿元。
  (三)搭建投资管理平台,完善内控建设
  报告期内,公司进一步调整优化管理架构,一方面完善公司投资机制,全资子公司海药投资将公司整体对外投资项目进行统筹管理,严控投资风险;另一方面不断优化公司管理结构,梳理和完善内控制度建设。
  (四)进一步储备医疗产业项目,拓展医疗服务产业
  国家医疗改革进一步深化提速,医疗服务行业迎来健康发展重大时机,公司将把握产业结构调整的历史机会,加大力气拓展医疗服务业务,发挥产业资本优势,植入新兴的管理和激励理念,促进医疗服务板块与其他大健康业务形成良好的互补。
  公司旗下鄂钢医院上半年完成收入5790万元,其收入结构不断优化,收购后管理整合初见成效。
  控股子公司郴州市第一人民医院东院有限公司上半年持续推动各项工程建设,争取年内顺利开业。
  (五)中药产业板块
  公司控股子公司廉桥药都通过建设中药材交易和存储平台,整合中药产业上下游资源,通过收购中药饮片厂及中药材公司,并以部分中药材品种经营为突破口,建立行业标准,努力发展成为区域龙头。
  (六)互联网医疗板块
  参股企业亚德科技继续推进贵州省人口健康平台项目建设等重点项目,参股公司金圣达也不断深化和扩大与医疗机构的合作,不断扩大远程心电、远程病理、远程影像、远程疑难病会诊、远程胎心监护等业务,公司将进一步把握医改和全民健康的政策规划,整合各类医疗信息资源,通过信息化手段,打破各医疗机构之间的信息孤岛,建立真正意义上的医联体模式新通道,同时对个体提供配套服务,带动各板块业务创新发展。
  报告期内,公司实现营业收入76320.29万元,较上年同期增长0.22%;2017年1—6月,归属于上市公司股东的净利润11357.61万元,较上年同期下降0.89%。

  二、报告期内公司从事的主要业务公司是否需要遵守特殊行业的披露要求
  (一)主要业务
  公司业务布局药品研发制造、生物医药、医疗器械、互联网医疗及医疗服务几大板块,目前以药品及医疗器械研发、生产和销售为主。
  1、公司主要产品包括六个系列,分别为头孢制剂系列、肠胃药系列、肿瘤药系列、人工耳蜗系列、原料药和中间体系列及其他产品。
  2、医疗服务:主要是全资子公司鄂州医院管理公司旗下的三级乙等综合医院鄂钢医院开展的综合医
  疗服务。
  (二)公司经营模式
  公司拥有独立完整的采购、生产和销售体系,并根据自身情况、市场规则和运作机制,独立开展经营活动。
  1、采购模式
  公司以销售预算、生产计划及原材料安全库存量为依据编制采购计划,向市场招标进行采购,通过比质比价择优采购。物料验收合格后,采购部门核对单据无误后通过ERP系统启动结算流程。
  2、生产模式
  公司生产实行以销定产的方式,生产计划按照客户需求、销售计划及安全库存标准制定。
  各生产子公司对产品的制造过程、工艺纪律、卫生规范、质量控制按照法律法规及规章制度进行管理。
  3、销售模式
  (1)制剂及中成药销售模式
  公司直接参与各地区药品招标,中标品种按国家规定的两票制执行销售,通过配送公司将药品配送到医院。公司一级经销商、二级分销商遍布全国,形成了较为完整的营销网络。公司部分肠胃康药品以与国外经销商合作的形式对外出口。
  (2)原料药及中间体销售模式
  公司主要通过参展、拜访等方式,对公司产品进行市场推广,征集客户需求;直接参与下游客户就某些采购量较大的原材料组织的招标活动。目前,公司医药原料药和中间体已经积累了较高的知名度和市场信誉,公司部分原料药和中间体产品向国外贸易商或制药公司出口。
  (3)人工耳蜗销售模式
  人工耳蜗产品主要采用直销和分销相结合的销售模式。截止2016年底,上海力声特已在上海、北京、湖南、江苏、山东等省市设立数十家人工耳蜗临床中心,直接负责人工耳蜗销售及维护、升级工作。此外,上海力声特在江苏、安徽、河南、山东等十几个省份目标市场建立办事处网点,加大了产品推广力度;在直销覆盖区域外通过经销商销售。在渠道建设方面,力声特加大公益项目开发力度,开展人工耳蜗救助项目,推广设立“启聪助听”康复基地。
  (三)药品项目的研发、生产及销售概况
  1、已进入注册程序的药品名称、注册分类、适应症或者功能主治、注册所处的阶段、进展情况。
  2、已纳入省级、国家级的《医保药品目录》的主要产品。
  3、本报告期及去年同期销售额占公司同期主营业务收入10%以上的主要药品。

  三、核心竞争力分析
  (一)产业链优势
  公司产业链布局架构基本搭建成形。在化学制剂方面,公司已经具备从中间体到原料药再到化学制剂的全产业链生产技术与能力。公司将不断优化生产流程与工艺,提高技术保障,以获得较大的成本优势,保证自身产品原材料供应稳定,增强质量及成本可控程度,维持主要产品的市场竞争优势。
  (二)研发优势
  公司持续关注化学药品、生物医疗器械、生物制药三大板块的研发,坚持三级研发体系的构建,推动三级互动的研发模式和良性循环。并与多所高校、医学研究机构建立了长期稳定的技术交流与合作关系。
  通过消化、吸收国际先进经验快速提高自身研发水平,大幅提高研发成功率、缩短研发时间以及上市销售时间。报告期,公司筛选的部分仿制药品正按计划开展质量和疗效一致性评价的研究开发工作,同时继续推进注射用盐酸苯达莫司汀、奥美拉唑碳酸氢钠干混悬剂Ⅱ期临床试验,确定氟非尼酮、多立培南、替比培南研究方案及计划。
  (三)市场营销优势
  公司具有完善的营销网络。公司设立了临床学术推广、代理分销、零售终端销售和国际贸易四大销售体系。通过优化销售模式,加强终端管理,强化学术支持,深化临床合作等措施,整合营销资源,形成闭环化管理;在市场细分领域不断巩固核心产品,以达到存量业务稳健经营和增量业务扩展的有效结合,不断提高产品的市场渗透力和覆盖率。
  (四)互联网医疗竞争优势
  公司全资子公司海药大健康管理(北京)有限公司继续整合各类医疗信息资源,同时公司的联营企业亚德科技、金圣达均已开展互联网医疗相关业务。通过上述产业布局积累了丰富的行业经验和较强的业务能力,为公司加快布局互联网医疗提供了先发优势。

  四、公司面临的风险和应对措施
  (一)政策风险
  公司主要药品已进入国家基本医疗保险药品目录,受新版GMP和GSP推进、招标延缓、医保控费、药费占比控制等行业政策管控加强等因素影响,公司部分产品售价可能会出现毛利率下降,对业绩增长带来不确定性。
  公司将不断加强销售渠道建设,严格控制成本,加快新产品研发推广以应对药品价格下降对业绩增长造成的影响。
  (二)研发风险
  公司所处制药行业竞争激烈,需要通过大量的研究和投入来保持技术的先进性和产品竞争优势。但产品的研究和开发过程可能时间较长,并且是否能形成适合市场需求的产品具有一定不确定性。新药注册一般要经历从临床前研究、临床试验批件报批、临床试验、药品生产批文报批、取得药品批文等环节,整个过程周期较长、环节较多,审批结果具有不确定性,存在研发风险。
  公司将采用原创新药研发和仿制药研发相结合方式,全面提高研发水平,通过消化、吸收国际先进经验快速提高自身研发水平,大幅提高研发成功率、缩短研发时间。
  (三)规模扩张引起的集团化管理风险
  公司所处医药及医疗行业处于快速发展和变革阶段,市场竞争日益激烈,机遇与挑战并存。随着新版块布局实施,公司资产和业务规模快速扩张,公司的管理跨度也增大,对管理层的管理与协调能力,以及公司在文化及资源融合方面、技术开发、市场开拓方面提出了更高的要求。
  公司将立足于公司自身特点和优势,推进各业务板块的梳理和调整,紧跟市场发展趋势,加强自身技术、管理水平及服务质量,以增强公司竞争优势。 收起▲